1-5 of 5
Brian Lestini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Suresh S. Ramalingam, Matthew D. Hellmann, Mark M. Awad, Hossein Borghaei, Justin Gainor, Julie Brahmer, David R. Spigel, Martin Reck, Kenneth J. O'Byrne, Luis Paz-Ares, Kim Zerba, Xuemei Li, William J. Geese, George Green, Brian Lestini, Joseph D. Szustakowski, Han Chang, Neal Ready
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT078.
https://doi.org/10.1158/1538-7445.AM2018-CT078
Published: 01 July 2018
View article titled, Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
Journal Articles

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Fei Su, William D. Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Min Jung Kim, Kerstin Trunzer, Richard J. Lee, Kathleen Schostack, Jade Carter, Thomas Albert, Soren Germer, Jim Rosinski, Mitchell Martin, Mary Ellen Simcox, Brian Lestini, David Heimbrook, Gideon Bollag
Journal: Cancer Research
Cancer Res (2012) 72 (4): 969–978.
https://doi.org/10.1158/0008-5472.CAN-11-1875
Published: 14 February 2012
View article titled, Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Open the PDF for Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2012) 72 (3): 779–789.
https://doi.org/10.1158/0008-5472.CAN-11-2941
Published: 31 January 2012
View article titled, Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Open the PDF for Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract #3269: RNA interference reveals heterogeneous pro-survival BH protein addiction and therapy resistance patterns in neuroblastoma

Brian Lestini, Kelly Goldsmith, Niel Chen, Xueyuan Liu, Michael Hogarty
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3269.
Published: 01 May 2009
View article titled, Abstract #3269: RNA interference reveals heterogeneous pro-survival BH protein addiction and therapy resistance patterns in neuroblastoma
Journal Articles

BH3 response profiles from isolated neuroblastoma mitochondria predict sensitivity to discrete BH antagonists

Kelly Goldsmith, Brian Lestini, Ashish Bhumbla, Laura Ip, Bruce Pawel, Xueyuan Liu, Michael Hogarty
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 1626.
Published: 01 May 2008
View article titled, BH3 response profiles from isolated neuroblastoma mitochondria predict sensitivity to discrete BH antagonists